

22/09/200414:44Print selected from Online session

G' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

84.83

85.25

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 14:39:26 ON 22 SEP 2004

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

=> "phosphatidyl serine" and sodium and "calcium salts" and (immunogenicity or "immune response" or antigenicity)

16 FILES SEARCHED...

28 FILES SEARCHED...

40 FILES SEARCHED...

55 FILES SEARCHED...

7 FILE USPATFULL

1 FILE WPIDS

72 FILES SEARCHED...

1 FILE WPINDEX

3 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L1 QUE "PHOSPHATIDYL SERINE" AND SODIUM AND "CALCIUM SALTS" AND (IMMUNOGENICITY OR "IMMUNE RESPONSE" OR ANTIGENICITY)

=> file uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.85

88.10

FILE 'USPATFULL' ENTERED AT 14:42:41 ON 22 SEP 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 21 Sep 2004 (20040921/PD)

FILE LAST UPDATED: 21 Sep 2004 (20040921/ED)

HIGHEST GRANTED PATENT NUMBER: US6795973

HIGHEST APPLICATION PUBLICATION NUMBER: US2004181840

CA INDEXING IS CURRENT THROUGH 21 Sep 2004 (20040921/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 21 Sep 2004 (20040921/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2004

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2004

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

23/09/200414:23Print selected from Online session

FILE 'HOME' ENTERED AT 14:17:35 ON 23 SEP 2004

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 14:17:58 ON 23 SEP 2004

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

=> "phosphatidyl serine" and "factor VIII" and ((reduce or reduced or decrease or decreased) (p) immunogenicity)

- 0\* FILE ADISNEWS
- 0\* FILE AQUALINE
- 0\* FILE ANTE
- 0\* FILE BIOCOMMERCE
- 0\* FILE BIOENG
- 0\* FILE BIOTECHABS
- 0\* FILE BIOTECHDS
- 0\* FILE BIOTECHNO

15 FILES SEARCHED...

- 0\* FILE CEABA-VTB
- 0\* FILE CIN

27 FILES SEARCHED...

35 FILES SEARCHED...

- 0\* FILE ESBIODASE
- 0\* FILE FEDRIP
- 0\* FILE FOMAD
- 0\* FILE FOREGE
- 0\* FILE FROSTI
- 0\* FILE FSTA
- 0\* FILE KOSMET
- 0\* FILE MEDICONF

50 FILES SEARCHED...

- 0\* FILE NTIS
- 0\* FILE NUTRACEUT
- 0\* FILE PASCAL
- 0\* FILE PHARMAML

64 FILES SEARCHED...

- 8 FILE USPATFULL
- 4 FILE USPAT2
- 0\* FILE WATER
- 1 FILE WPIDS

73 FILES SEARCHED...

- 1 FILE WPINDEX

4 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L1 QUE "PHOSPHATIDYL SERINE" AND "FACTOR VIII" AND ((REDUCE OR REDUCED OR DECREASE OR DECREASED) (P) IMMUNOGENICITY)

23/09/200414:23Print selected from Online session

=> file USPatfull uspat2 wpids

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.42

3.63

FILE 'USPATFULL' ENTERED AT 14:21:16 ON 23 SEP 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:21:16 ON 23 SEP 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:21:16 ON 23 SEP 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

=> "phosphatidyl serine" and "factor VIII" and ((reduce or reduced or decrease or decreased) (p) immunogenicity)

L2 13 "PHOSPHATIDYL SERINE" AND "FACTOR VIII" AND ((REDUCE OR REDUCED OR DECREASE OR DECREASED) (P) IMMUNOGENICITY)

=> dup remove

ENTER REMOVE, IDENTIFY, ONLY, OR (?): remove

ENTER L# LIST OR (END):L2

'REMOVE' IS NOT VALID. VALID FILE NAMES ARE 'USPATFULL, USPAT2, WPIDS'

You have entered a file name of duplicates to keep that is not referenced by any of the L#s specified for this DUPLICATE command.

The file names of duplicates that can be kept are listed above.

Please enter one of these file names.

=> d ti 1-13

L2 ANSWER 1 OF 13 USPATFULL on STN

TI Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions

L2 ANSWER 2 OF 13 USPATFULL on STN

TI Ex-vivo and in vivo factor XII gene therapy for hemophilia A and B

L2 ANSWER 3 OF 13 USPATFULL on STN

TI Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof

L2 ANSWER 4 OF 13 USPATFULL on STN

TI Novel method for targeted delivery of nucleic acids

L2 ANSWER 5 OF 13 USPATFULL on STN

TI Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof

L2 ANSWER 6 OF 13 USPATFULL on STN

TI Novel method for targeted delivery of nucleic acids

L2 ANSWER 7 OF 13 USPATFULL on STN

TI Method for targeted delivery of nucleic acids

L2 ANSWER 8 OF 13 USPATFULL on STN

TI Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof

L2 ANSWER 9 OF 13 USPAT2 on STN

TI Single-chain antigen-binding proteins capable of glycosylation,  
production and uses thereof

L2 ANSWER 10 OF 13 USPAT2 on STN

TI Single-chain polypeptides for targeted delivery of nucleic acids

L2 ANSWER 11 OF 13 USPAT2 on STN

TI Single-chain antigen-binding proteins capable of glycosylation,  
production and uses thereof

L2 ANSWER 12 OF 13 USPAT2 on STN

TI Method for targeted delivery of nucleic acids

L2 ANSWER 13 OF 13 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

TI Reducing the antigenicity/immunogenicity of a therapeutic agent and  
treatment of e.g. hemophilia involves forming complex of the therapeutic  
agent with serine containing phospholipid in presence of sodium and  
calcium salts.

=> d ab bib 13

L2 ANSWER 13 OF 13 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

AB WO2004071420 A UPAB: 20040915

NOVELTY - Reducing the antigenicity/**immunogenicity** of a  
therapeutic agent selected from peptide, polypeptide and protein involves:  
(a) forming a complex (C) of the therapeutic agent with a serine  
containing phospholipid in the presence of sodium and calcium salts. The  
antigenicity/**immunogenicity** of the therapeutic agent is  
**reduced** when complexed with the serine containing phospholipid.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for  
lipid-protein complexes that are formed by incubating a protein with the  
serine containing phospholipid in the presence of the sodium salt (100 nM)  
and the calcium salt (5 nM). (C2) Migrates at the interface of 10 - 14%  
dextran gradient

ACTIVITY - Hemostatic; Immunosuppressant.  
Test details are described, but no proper results are given.

MECHANISM OF ACTION - None given.

USE - For reducing the antigenicity/**immunogenicity** of a  
therapeutic agent e.g. peptide, polypeptide and protein (claimed). For the  
treatment of diseases e.g. hemophilia.

ADVANTAGE - The antigenicity/**immunogenicity** of the  
therapeutic agent is **reduced** when complexed with the serine  
containing phospholipid. The complex improves the stability of the  
therapeutic agent.

Dwg.0/8

AN 2004-615911 [59] WPIDS

DNC C2004-221893

TI Reducing the antigenicity/immunogenicity of a therapeutic agent and  
treatment of e.g. hemophilia involves forming complex of the therapeutic  
agent with serine containing phospholipid in presence of sodium and  
calcium salts.

DC B04

IN BALASUBRAMANIAN, S V; PUROHIT, V S; RAMANI, K; STRAUBINGER, R M

PA (UYNY) UNIV NEW YORK STATE RES FOUND

CYC 108

PI WO 2004071420 A2 20040826 (200459)\* EN 31

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE  
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

23/09/200414:23Print selected from Online session

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE  
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG  
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ  
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG  
US UZ VC VN YU ZA ZM ZW

ADT WO 2004071420 A2 WO 2004-US3269 20040205  
PRAI US 2003-445134P 20030205

```
>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> "phosphatidyl serine" and sodium and "calcium salts" and (immunogenicity or "immune response" or antigenicity)

```
7169 "PHOSPHATIDYL"
2 "PHOSPHATIDYLS"
7170 "PHOSPHATIDYL"
("PHOSPHATIDYL" OR "PHOSPHATIDYLS")
46740 "SERINE"
1669 "SERINES"
47219 "SERINE"
("SERINE" OR "SERINES")
1448 "PHOSPHATIDYL SERINE"
("PHOSPHATIDYL" (W) "SERINE")
508369 SODIUM
75 SODIUMS
508376 SODIUM
(SODIUM OR SODIUMS)
300259 "CALCIUM"
68 "CALCIUMS"
300261 "CALCIUM"
("CALCIUM" OR "CALCIUMS")
371060 "SALTS"
12678 "CALCIUM SALTS"
("CALCIUM" (W) "SALTS")
17973 IMMUNOGENICITY
156 IMMUNOGENICITIES
17987 IMMUNOGENICITY
(IMMUNOGENICITY OR IMMUNOGENICITIES)
84338 "IMMUNE"
22 "IMMUNES"
84341 "IMMUNE"
("IMMUNE" OR "IMMUNES")
993662 "RESPONSE"
118814 "RESPONSES"
1007727 "RESPONSE"
("RESPONSE" OR "RESPONSES")
36636 "IMMUNE RESPONSE"
("IMMUNE" (W) "RESPONSE")
10692 ANTIGENICITY
89 ANTIGENICITIES
10710 ANTIGENICITY
(ANTIGENICITY OR ANTIGENICITIES)
```

L2 7 "PHOSPHATIDYL SERINE" AND SODIUM AND "CALCIUM SALTS" AND (IMMUNOGENICITY OR "IMMUNE RESPONSE" OR ANTIGENICITY)

=> d ti 1-7

L2 ANSWER 1 OF 7 USPATFULL on STN

TI Mucoscal vaccine and methods for using the same

L2 ANSWER 2 OF 7 USPATFULL on STN

TI Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction

L2 ANSWER 3 OF 7 USPATFULL on STN

TI Optoacoustic contrast agents and methods for their use

L2 ANSWER 4 OF 7 USPATFULL on STN

TI Vaccine compositions containing liposomes

L2 ANSWER 5 OF 7 USPATFULL on STN

TI Pharmaceutical composition for the therapy of cerebral thrombosis

L2 ANSWER 6 OF 7 USPATFULL on STN

TI Jomol derivatives as agents for the use in malignant tumors and lowered immune defenses

L2 ANSWER 7 OF 7 USPATFULL on STN

TI Radioactive Jomol, its derivatives, processes for the production of these compounds, their use and product

=> d ab bib 5

L2 ANSWER 5 OF 7 USPATFULL on STN

AB A pharmaceutical composition effective for the therapy of cerebral thrombosis, particularly acute cerebral thrombosis, which is in the form of a fat emulsion containing an isocarbacyclin having a specific structure, and a method for the therapy of cerebral thrombosis.

AN 97:20551 USPATFULL

TI Pharmaceutical composition for the therapy of cerebral thrombosis

IN Mizushima, Yutaka, 1-1-11, Umeaoka, Setagaya-ku, Tokyo 154, Japan  
Bannai, Kiyoshi, Scardale, NY, United States  
Nakayana, Shigeru, Tokyo, Japan

PA Teijin, Limited, Osaka, Japan (non-U.S. corporation)  
Taisho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
Mizushima, Yutaka, Tokyo, Japan (non-U.S. individual)

PI US 5610182 19970311  
WO 9417804 19940818

AI US 1994-313244 19941003 (8)  
WO 1994-JP142 19940202  
19941003 PCT 371 date  
19941003 PCT 102(e) date

PRAI JP 1993-16321 19930203

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Sherman and Shalloway

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1286

CAS INDEXING IS AVAILABLE FOR THIS PATENT.